STOK Stoke Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: RNA-based medicines using proprietary TANGO platform to upregulate protein expression for treating severe genetic diseases
• • New focus: Phase 3 study of zorevunersen for Dravet syndrome initiated May 2025, plus Phase 1 study of STK-002 for autosomal dominant optic atrophy
• • Strategic shift: Emphasis on rapid commercial preparation in US, Canada, Mexico for zorevunersen; global commercial partner Biogen for other territories
• • Notable metric: EMPEROR Phase 3 enrollment target ~150 patients; OLE studies sustained seizure reduction through 3 years in 74 patients enrolled
• • Unique fact: Zorevunersen granted FDA Breakthrough Therapy Designation Dec 2024; Phase 1/2a and OLE data published in New England Journal of Medicine March 2026

Risk Factors

• • Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development
• • Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations
• • Supply chain risk: dependency on third-party CMOs for clinical and commercial manufacturing supply and backup sources
• • Competitive risk: uncertainty if regulatory labeling excludes secondary endpoints potentially weakening competitive positioning
• • Financial risk: history of losses with anticipated continued deficits and need for additional funding before profitability achievable

Management Discussion & Analysis

• • Revenue $184.4M in 2025 vs $36.6M in 2024, up $147.8M mainly from Biogen collaboration ($168.3M in 2025) offset by Acadia decline
• • Net loss $6.9M in 2025 vs $89.0M in 2024; operating loss improved to $20.6M from $101.4M; operating margin approx. -11.2% vs -277.1%
• • Best segment: Biogen collaboration revenue $168.3M in 2025, no revenue in 2024; worst: ADOA R&D costs mostly flat ($5.1M vs $5.8M) with limited impact on revenue
• • Cash $390.9M at end 2025 vs $246.7M end 2024; capital raised via equity offerings netting $168.8M in 2025; no dividends or buybacks disclosed; expected to fund operations into 2028
• • Forward outlook: expect increased R&D and SG&A costs to support clinical development and commercialization; risks from clinical, regulatory, and financing uncertainties remain

What are the latest STOK SEC filings in 2026?

Stoke Therapeutics, Inc. (STOK) has filed a 10-K annual report on March 16, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did STOK file its most recent 10-K annual report?

Stoke Therapeutics, Inc. (STOK) filed its most recent 10-K annual report on March 16, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view STOK 10-Q quarterly reports?

Stoke Therapeutics, Inc. (STOK)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every STOK 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has STOK filed recently?

Stoke Therapeutics, Inc. (STOK)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find STOK insider trading activity (Form 4)?

SignalX aggregates every STOK Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does STOK file with the SEC?

Stoke Therapeutics, Inc. (STOK) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new STOK filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Stoke Therapeutics, Inc. (STOK).

What is STOK's SEC CIK number?

Stoke Therapeutics, Inc. (STOK)'s SEC CIK (Central Index Key) number is 1623526. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1623526 to look up all STOK filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find STOK return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Stoke Therapeutics, Inc. (STOK) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.